Viral vectors in cancer immunotherapy /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Formato: Electrónico eBook
Idioma:Inglés
Publicado: [S.l.] : Academic Press, 2023.
Colección:International review of cell and molecular biology ; volume 379
Temas:
Cancer > Immunotherapy.
Cancer > Gene therapy.
Genetic vectors > Therapeutic use.
Immunotherapy.
Cancer Vaccines.
Oncolytic Virotherapy.
Oncolytic Viruses.
Genetic Therapy.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Front Cover
  • Series page
  • International Review of CELL AND MOLECULARBIOLOGY
  • Copyright
  • Contents
  • Contributors
  • Chapter One: Viral vectors engineered for gene therapy
  • 1 Introduction
  • 2 Viral vectors for gene therapy
  • 3 Gene therapy applications using viral vectors
  • 3.1 Cancer therapy
  • 3.2 Cardiovascular and metabolic diseases
  • 3.3 Hematological diseases
  • 3.4 Neurological disorders
  • 3.5 Muscular diseases
  • 3.6 Immunodeficiency
  • 3.7 Infectious diseases
  • 3.8 Other diseases
  • 4 Challenges for viral vector-based gene therapy
  • 5 Conclusions and perspectives
  • References
  • Chapter Two: Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicityCheckpoint blockade meets gene therapy
  • 1 Introduction
  • 2 Immune checkpoints in cancer immunotherapy
  • 3 Types of antibodies used in cancer immunotherapy
  • 4 Local delivery of immune checkpoint inhibitors: Prospects for gene therapy
  • 5 Oncolytic viruses expressing ICIs
  • 6 Non-oncolytic vectors expressing ICIs
  • 7 Self-amplifying RNA vectors expressing ICIs
  • 8 Combination of vectors expressing ICIs with other therapies
  • 8.1 Combination with systemically administered ICIs
  • 8.2 Combination with CAR-T cells
  • 8.3 Combination with depletion of immunosuppressive cells
  • 8.4 Combination with radiation and chemotherapy
  • 9 Conclusions
  • Competing interests
  • Acknowledgements
  • References
  • Chapter Three: Armored modified vaccinia Ankara in cancer immunotherapy
  • 1 Introduction
  • 2 MVA as potent immune activator
  • 2.1 Cell and tissue tropism
  • 2.2 Innate immune activation
  • 2.3 Induction of cell death
  • 2.4 Generation of adaptive immune responses
  • 3 Tumor antigens encoded in MVA vaccines
  • 3.1 HER2
  • 3.2 P53
  • 3.3 Brachyury
  • 3.4 5T4
  • 3.5 MUC1 and CEA
  • 3.6 Self- and virus-derived neoantigens.
  • 3.7 Novel TAA candidates
  • 4 MVA cancer vaccines expressing immune modulatory molecules
  • 4.1 MVA-TRICOM
  • 4.2 MVA-CD40L
  • 4.3 MVA-IL-2
  • 4.4 Novel candidates
  • 5 Maximizing MVA cancer vaccine effectiveness: A comprehensive exploration of delivery routes
  • 5.1 Alternative immunization routes to enhance MVA-based immune modulation
  • 5.2 The impact of immunization routes on the efficacy of armed MVA
  • 6 Conclusions and outlook
  • References
  • Chapter Four: Alphaviruses in cancer immunotherapyAlphaviruses in cancer immunotherapy
  • 1 Introduction
  • 2 Alphavirus vectors
  • 2.1 Recombinant particles
  • 2.2 Oncolytic alphaviruses
  • 2.3 RNA replicon vectors
  • 2.4 DNA replicon vectors
  • 3 Alphavirus-based cancer therapy
  • 3.1 Antitumor, cytotoxic, and suicide genes
  • 3.2 Cancer vaccines
  • 3.3 Cancer immunotherapy
  • 3.4 Oncolytic alphaviruses
  • 4 Alphaviruses in comparison to other approaches
  • 4.1 Conventional non-viral vectors versus self-replicating alphavirus DNA vectors
  • 4.2 Other viral vectors versus recombinant self-replicating alphavirus particles
  • 4.3 Synthetic mRNA molecules versus self-replicating RNA replicons
  • 5 Conclusions
  • References
  • Chapter Five: Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical successOncolytic viruses as treatment for adult and pediatric high-grade gliomas
  • 1 High-grade gliomas
  • 2 Oncolytic viruses
  • 3 Adult high-grade glioma clinical trials
  • 3.1 Herpes simplex virus type-1(HSV-1)
  • 3.2 Adenoviruses
  • 3.3 Other oncolytic viruses
  • 4 Pediatric high-grade glioma clinical trials
  • 5 Discussion and future perspectives
  • References
  • Chapter Six: Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapiesOncolytic viruses in hematological malignancies.
  • 1 Introduction
  • 2 Families of oncolytic viruses and mechanisms of action
  • 2.1 General biology of viruses
  • 2.2 Family of viruses with potential application in oncolytic therapy
  • 2.3 Virotherapy principles: cell signaling and immunopathogenesis in viral infection response
  • 2.4 Viral oncolytic strategies, cell signaling disruption, and immune reprogramming
  • 3 Virotherapy approaches in hematological malignancies
  • 3.1 Precursor myeloid malignancies
  • 3.2 Precursor lymphoid malignancies
  • 3.3 Myeloproliferative neoplasms
  • 3.4 Mature lymphoid malignancies
  • 3.4.1 B cell-derived malignancies
  • 3.4.2 T cell-derived malignancies
  • 3.5 Multiple myeloma
  • 3.6 Combinatorial strategies to enhance immunogenic cell death
  • 4 Conclusion
  • References
  • Chapter Seven: Oncolytic virotherapy in lung cancerOncolytic virotherapy in lung cancer
  • 1 The lung cancer scenario
  • 2 Immune therapy in lung cancer
  • 3 Oncolytic virotherapy
  • 3.1 DNA viruses
  • 3.1.1 Adenoviruses
  • 3.1.2 Poxviruses
  • 3.1.3 Herpesvirus
  • 3.1.4 Parvovirus
  • 4 RNA viruses
  • 4.1 Paramyxovirus
  • 4.2 Rhabdovirus
  • 4.3 Orthomyxovirus
  • 4.4 Picornavirus
  • 4.5 Reovirus
  • 5 Discussion
  • Acknowledgments
  • References
  • Chapter Eight: Rational selection of an ideal oncolytic virus to address current limitations in clinical translationRational selection of an ideal oncolytic virus to address current limitations in clinical translation
  • 1 Introduction
  • 2 Oncolytic virus landscape
  • 2.1 Adenovirus
  • 2.2 Herpes simplex virus
  • 2.3 Vaccinia virus
  • 2.4 Reovirus
  • 2.5 Measles virus
  • 3 Ideal properties of an oncolytic virus therapy
  • 4 Vesicular stomatitis virus
  • 4.1 Selectivity
  • 4.2 Therapeutic transgenes
  • 4.3 Genome stability
  • 5 Conclusion
  • Competing interests
  • Acknowledgments
  • References
  • Backcover.

Ejemplares similares